Abstract:This review describes a method by which the human natural anti-Gal antibody can be exploited as an endogenous adjuvant for targeting autologous tumor vaccines to antigen-presenting cells (APCs). Tumor cells remaining in the patient after completion of surgery, radiation, and chemotherapy are the cause of tumor relapse. These residual tumor cells can not be detected by imaging, but their destruction may be feasible by active immunotherapy. Since specific tumor-associated antigens (TAAs) have not been identified for the majority of cancers, irradiated autologous tumor vaccines have been considered as an immunotherapy treatment that may elicit an immune response against the residual tumor cells expressing TAAs. However, tumor cells evolve in cancer patients in a stealthy way, i.e., they are not detected by APCs, even in the form of vaccine. Effective targeting of tumor vaccines for uptake by APCs is a prerequisite for eliciting an effective immune response which requires transport of the vaccine by APCs from the vaccination site to the draining lymph nodes. In the lymph nodes, the APCs transporting the vaccine process and present peptides, including the autologous TAA peptides for activation of the tumor-specific T cells. The required targeting of vaccines to APCs is feasible in humans by the use of anti-Gal. This antibody interacts specifically with the alpha-gal epitope (Galalpha1-3Galbeta1-4GlcNAc-R) and is the only known natural IgG antibody to be present in large amounts in all humans who are not severely immunocompromised. The alpha-gal epitope can be synthesized on any type of human tumor cell by the use of recombinant alpha1,3galactosyltransferase (alpha1,3GT). Solid tumors obtained from surgery are homogenized and their membranes subjected to alpha-gal epitope synthesis. Similarly, alpha-gal epitopes can be synthesized on intact tumor cells from hematological malignancies. Administration of irradiated autologous tumor vaccines processed to express alpha-gal epitopes results in in situ opsonization of the vaccinating cells or cell membranes due to anti-Gal binding to these epitopes. The bound antibody serves to target the autologous tumor vaccine to APCs because the Fc portion of the antibody interacts with Fcgamma receptors on APCs. Since patients receive their own TAAs, the vaccine is customized for autologous TAAs in the individual patient. The repeated vaccination with such autologous tumor vaccines provides the immune system of each patient with an additional opportunity to be effectively activated by the autologous TAAs. In some of the immunized patients this activation may be potent enough to induce an immune-mediated eradication of the residual tumor cells expressing these TAAs.

Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed

Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination

A Cancer Vaccine-Mediated Postoperative Immunotherapy for Recurrent and Metastatic Tumors.

Hybrid Ginseng‐derived Extracellular Vesicles‐Like Particles with Autologous Tumor Cell Membrane for Personalized Vaccination to Inhibit Tumor Recurrence and Metastasis

Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy

Self-Metallized Whole Cell Vaccines Prepared by Microfluidics for Bioorthogonally Catalyzed Antitumor Immunotherapy.

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines

Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity

Self-Generating Gold Nanocatalysts in Autologous Tumor Cells for Targeted Catalytic Immunotherapy.

Neoantigen sequestrated autophagosomes as therapeutic cancer vaccines

PEGylated Tumor Cell Membrane Vesicles As a New Vaccine Platform for Cancer Immunotherapy.

Bifunctional Fusion Membrane‐Based Hydrogel Enhances Antitumor Potency of Autologous Cancer Vaccines by Activating Dendritic Cells

Injectable Adhesive Hydrogel as Photothermal‐Derived Antigen Reservoir for Enhanced Anti‐Tumor Immunity

Bis-2'-F-cGSASMP isomers encapsulated in cytidinyl/cationic lipids act as potent in situ autologous tumor vaccines

Autologous tumor antigens and boron nanosheet-based nanovaccines for enhanced photo-immunotherapy against immune desert tumors

In Situ Genetic Engineering of Host T-cells Based on Acellular Scaffold Strategy: a Big but Also Small Step for Solid Tumor Immunotherapy

Engineered Probiotic‐Based Personalized Cancer Vaccine Potentiates Antitumor Immunity through Initiating Trained Immunity

Targeting pan-tumor antigens to activating Fcγ receptors generates a novel dendritic cell tumor vaccine

ER-Targeting PDT Converts Tumors into In Situ Therapeutic Tumor Vaccines

Autologous-cancer-cryoablation-mediated Nanovaccine Augments Systematic Immunotherapy.

Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer